Do AlzChem Group's (ETR:ACT) Earnings Warrant Your Attention?
In contrast to all that, many investors prefer to focus on companies like AlzChem Group (ETR:ACT), which has not only revenues, but also profits. Now this is not to say that the company presents the best investment opportunity around, but profitability is a key component to success in business.
This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.
If a company can keep growing earnings per share (EPS) long enough, its share price should eventually follow. Therefore, there are plenty of investors who like to buy shares in companies that are growing EPS. Shareholders will be happy to know that AlzChem Group's EPS has grown 27% each year, compound, over three years. If the company can sustain that sort of growth, we'd expect shareholders to come away satisfied.
Careful consideration of revenue growth and earnings before interest and taxation (EBIT) margins can help inform a view on the sustainability of the recent profit growth. The music to the ears of AlzChem Group shareholders is that EBIT margins have grown from 11% to 14% in the last 12 months and revenues are on an upwards trend as well. Ticking those two boxes is a good sign of growth, in our book.
The chart below shows how the company's bottom and top lines have progressed over time. For finer detail, click on the image.
View our latest analysis for AlzChem Group
Of course the knack is to find stocks that have their best days in the future, not in the past. You could base your opinion on past performance, of course, but you may also want to check this interactive graph of professional analyst EPS forecasts for AlzChem Group.
It's pleasing to see company leaders with putting their money on the line, so to speak, because it increases alignment of incentives between the people running the business, and its true owners. AlzChem Group followers will find comfort in knowing that insiders have a significant amount of capital that aligns their best interests with the wider shareholder group. To be specific, they have €42m worth of shares. This considerable investment should help drive long-term value in the business. Even though that's only about 3.0% of the company, it's enough money to indicate alignment between the leaders of the business and ordinary shareholders.
You can't deny that AlzChem Group has grown its earnings per share at a very impressive rate. That's attractive. Further, the high level of insider ownership is impressive and suggests that the management appreciates the EPS growth and has faith in AlzChem Group's continuing strength. Fast growth and confident insiders should be enough to warrant further research, so it would seem that it's a good stock to follow. If you think AlzChem Group might suit your style as an investor, you could go straight to its annual report, or you could first check our discounted cash flow (DCF) valuation for the company.
While opting for stocks without growing earnings and absent insider buying can yield results, for investors valuing these key metrics, here is a carefully selected list of companies in DE with promising growth potential and insider confidence.
Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Google DeepMind has grand ambitions to ‘cure all diseases' with AI. Now, it's gearing up for its first human trials
Alphabet's Isomorphic Labs is preparing to launch human trials of AI-designed drugs, its president, Colin Murdoch, told Fortune. Born from DeepMind's AlphaFold breakthrough, the company is pairing cutting-edge AI with pharma veterans to design medicines faster, cheaper, and more accurately. Alphabet's secretive drug discovery arm, Isomorphic Labs, is getting ready to start testing its AI-designed drugs in humans, Colin Murdoch, Isomorphic Labs president and Google DeepMind's chief business officer, told Fortune. 'There are people sitting in our office in King's Cross, London, working, and collaborating with AI to design drugs for cancer,' Murdoch said during an interview in Paris. 'That's happening right now.' After years in development, Murdoch says human clinical trials for Isomorphic's AI-assisted drugs are finally in sight. 'The next big milestone is actually going out to clinical trials, starting to put these things into human beings,' he said. 'We're staffing up now. We're getting very close.' The company, which was spun out of DeepMind in 2021, was born from one of DeepMind's most celebrated breakthroughs, AlphaFold, an AI system capable of predicting protein structures with a high level of accuracy. Interactions of AlphaFold progressed from being able to accurately predict individual protein structures to modeling how proteins interact with other molecules like DNA and drugs. These leaps made it far more useful for drug discovery, helping researchers design medicines faster and more precisely, turning the tool into a launchpad for a much larger ambition. 'This was the inspiration for Isomorphic Labs,' Murdoch said of AlphaFold. 'It really demonstrates that we could do something very foundational in AI that could help unlock drug discovery.' In 2024, the same year it released AlphaFold 3, Isomorphic signed major research collaborations with pharma companies Novartis and Eli Lilly. A year later, in April 2025, Isomorphic Labs raised $600 million in its first-ever external funding round, led by Thrive Capital. The deals are part of Isomorphic's plan to build a 'world-class drug design engine,' a system that combines machine learning researchers with pharma veterans to design new medicines faster, more cheaply, and with a higher chance of success. As part of the deals with major pharma players, Isomorphic supports existing drug programs, but it also designs its own internal drug candidates in areas such as oncology and immunology, with the aim of eventually licensing them out after early-stage trials. 'We identify an unmet need, and we start our own drug design programs. We develop those, put them into human clinical trials… we haven't got that yet, but we're making good progress,' he said. Today, pharma companies often spend millions attempting to bring a single drug to market, sometimes with just a 10% chance of success once trials begin. Murdoch believes Isomorphic's tech could radically improve those odds. 'We're trying to do all these things: speed them up, reduce the cost, but also really improve the chance that we can be successful,' he says. He wants to harness AlphaFold's technology to get to a point where researchers have 100% conviction that the drugs they are developing are going to work in human trials. 'One day we hope to be able to say — well, here's a disease, and then click a button and out pops the design for a drug to address that disease,' Murdoch said. 'All powered by these amazing AI tools.' This story was originally featured on
Yahoo
an hour ago
- Yahoo
Before You Buy That 'Cheap' Stock, Read the Proxy, Not The Pitch Deck
The deeper you dig into companies, the more dysfunction you find. This is not due to businesses being inherently broken, but rather because the incentives are flawed. On the surface, stocks can look cheap. Screens flag low multiples, analyst notes highlight growth potential, and management sounds confident on the call. But beneath that narrative, capital often gets quietly misallocated. Empire-building creeps in. Decisions tilt toward boosting bonuses, not shareholder value. And the metrics that matter most, the ones buried in incentive structures and insider behavior, go ignored by most investors. As Amazon Doubles Down on Robotaxis, Is AMZN Stock a Buy? Why Citi Thinks Micron Stock Is Headed to $150 After Earnings Beat OpenAI's Partnership With Microsoft is Good, Says CEO Sam Altman; There's 'Tension,' But Already Planning 'Next Decade Together' Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. This is where the true significance emerges. If you don't monitor executive pay and insider moves, you're overlooking potential value leaks or, crucially, unlocked opportunities. These aren't soft signals. They're hard tells. The clues are in the proxy filings, the timing of stock sales, and the structure of performance hurdles. This issue isn't about corporate morality. It's about money. For investors who know where to look, misaligned governance isn't a red flag; it's a roadmap to alpha. Capital Allocation. The Hidden Cost Of Ego Capital allocation is where the quiet destruction of value often begins and it's rarely about incompetence. It's about incentives. Expect empire building when a CEO's bonus is based on top-line growth instead of return on invested capital (ROIC). That usually means overpaying for acquisitions, not because they're strategic, but because they build legacy. Cash gets hoarded instead of returned, while buybacks and dividends are treated as afterthoughts, despite being the most shareholder-friendly tools available. Look closer and you'll see companies issuing millions in stock-based compensation while continuing to dilute shareholders by printing more shares. Others hang onto underperforming divisions year after year, not because they add value but because breaking them up would shrink the C-suite. This isn't hypothetical. We've seen it in sprawling conglomerates that refuse to divest low-ROIC segments, in tech firms obsessed with topline over profit, and in boards that rubber-stamp comp plans designed to reward size not efficiency. The result? On paper, a stock appears inexpensive, yet it lacks the structural ability to increase value. The investor takeaway is simple: Read the proxy. Please disregard the glossy investor deck. What's buried in the footnotes of a compensation plan tells you far more than the income statement. Incentives, not narratives, dictate capital allocation in this context. Executive Compensation: Where The Real Priorities Lie At The Edge, we track dozens of these triggers across spinoffs, restructurings, and breakups. Why? Executive behavior concerning value unlocks more insights than any analyst report. When comp plans prioritize optics over outcomes, it's a red flag. However, when the incentives align with the creation of real shareholder value, it's a positive sign. Take (VLTO): Prior to the spin from Danaher, we flagged their LTIP structure as heavily performance-driven, measured on metrics like ROIC and TSR over three years, not revenue padding. This clarity indicated that management was pursuing a long-term strategy, and the market has appropriately rewarded them. In contrast, (ILMN) became a textbook example of what happens when executive compensation favors empire-building over accountability. Executive pay isn't just about fairness, it's about foresight. If management wins regardless of shareholder outcomes, you won't. Insider Behavior: The Tells You Can't Ignore In a world of carefully managed narratives, insider behavior is one of the few signals that's hard to fake. When insiders buy during periods of structural change, before the narrative becomes clear, it indicates strong conviction. When insiders are selling after the story has played out and retail investors have piled in, it often indicates a market peak. It's not just about the transaction; it's about timing, size, and frequency. Does a solitary, minor purchase follow a challenging quarter? That's merely surface-level activity. However, when multiple buys occur across management tiers, a phenomenon known as a bullish cluster, it signals a significant underlying trend. (ECG) serves as a prime example. In February 2025, three insiders—Marcy Maximillian J, Ryan Edward A, and Michael Della Rocca—each bought stock worth between $49k and $53k within days of one another. There was no flashy announcement or hype. Instead, they acted with a quiet conviction. Shortly after, ECG's stock surged nearly 69%, well before the market narrative caught up. Don't chase headlines; track behavior. And when the people who know the business best put real capital to work, we take notice. In a noisy market, that kind of signal is gold. Spinoffs: The Ultimate Incentive Transparency Test If you want to see what management really believes, watch what happens during a spinoff. Spinoffs compel executives to reveal their true intentions. Incentives get reset, structures rebuilt, and priorities laid bare, usually for the first time. The Form 10 is often more revealing than any investor deck, offering a raw look at how aligned (or not) leadership is with future shareholders. What should investors watch for? Start with the comp plan. 'Founder-like' pay structures where leadership takes equity over salary and ties it to long-term value creation are a bullish tell. If the former executives from the parent company maintain significant ownership in the spin-off and avoid selling their shares immediately after the separation, that is another positive indicator. When they tie equity awards to real performance hurdles (ROIC, TSR), rather than just revenue optics, it demonstrates their alignment with the right metrics. In spinoffs, incentives reset and clarity reaches its peak. Study these transactions closely because they offer the cleanest read on intent. If the incentives align, value usually follows. What Smart Investors Do Differently Smart investors don't just screen for valuation; they screen for behavior. They know governance isn't a checkbox. It's a signal. They probe beyond the earnings deck to understand who, how, and why they are receiving compensation. They treat insider behavior and compensation structure as core parts of the thesis, not footnotes. This is why you will outperform in special situations: You are not buying stories. You're buying setups, where incentives align, risk is asymmetric, and behavior signals what spreadsheets can't. Value Is Leaking. Are You Watching? Most investors chase earnings and price targets. But value doesn't leak from spreadsheets; it leaks from boardrooms. You're missing the setup and the upside if you're not monitoring insiders' actions, their compensation, and their beliefs. Incentives shape outcomes. Behavior reveals conviction. And in special situations, that's where the real alpha lives. On the date of publication, Jim Osman did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Chart of the Week: Wall Street Has Claimed Bitcoin—Now What?
"Wall Street is coming for bitcoin." That phrase used to spark both hope and fear across crypto circles. Today, it's no longer a future threat or a bullish promise—it's just reality. The original premise of bitcoin (or crypto in general)—an asset that is censorship-resistant and doesn't answer to any traditional financial institution or government—is fading fast as Wall Street giants (as well as powerful political figures) continue to establish their strong foothold in the digital assets space. During the early years of the digital assets revolution, bitcoin was celebrated as uncorrelated and unapologetically anti-establishment. TradFi asset classes like S&P 500 would rise and fall—bitcoin didn't care. What bitcoin did care about were the flaws in the traditional financial system, which are still here to this day. A major example in BTC's history that's not-so-talked about anymore is the 2013 Cyprus banking crisis. The crisis, which occurred due to overexposure of banks to overleveraged local property companies and amid Europe's debt crisis, saw deposits above 100,000 euros get a substantial haircut. In fact, 47.5% of uninsured deposits were seized. Bitcoin's response was to move sharply upward to, for the first time in its history, cross the $1,000 threshold. After a prolonged bear market over the collapse of Mt. Gox, the idea of mass adoption grew, with Wall Street's entry into the sector seen as a stamp of validation for bitcoin as it meant more liquidity, mass adoption and price maturity. That changed everything. The price might have matured, as evidenced by waning volatility. But let's face it—bitcoin is now just another macro-driven risk asset. "Bitcoin, once celebrated for its low correlation to mainstream financial assets, has increasingly exhibited sensitivity to the same variables that drive equity markets over short time frames," said NYDIC Research in a report. In fact, the correlation is now hovering near the higher end of the historical range, according to NYDIG's calculations. "Bitcoin's correlation with U.S. equities remained elevated through the end of the quarter, closing at 0.48, a level near the higher end of its historical range." Simply put, when there is blood on the street (Wall Street that is), bitcoin bleeds too. When Wall Street sneezes, bitcoin catches a cold. Even bitcoin's 'digital gold' moniker is under pressure. NYDIG notes that bitcoin's correlation to physical gold and the U.S. dollar is near zero. So much for the 'hedge' argument—at least for now. So why the shift? The answer is simple: to Wall Street, bitcoin is just another risk asset, not digital gold, which is synonymous with "safe haven." Investors are repricing everything from central bank policy whiplash to geopolitical tension—digital assets included. "This persistent correlation strength with U.S. equities can largely be attributed to a series of macroeconomic and geopolitical developments, the tariff turmoil and the rising number of global conflicts, which significantly influenced investor sentiment and asset repricing across markets," said NYDIG. And like it or not, this is here to stay—at least for a short to medium-term. As long as central bank policy, macro, and war-linked red headlines hit the tape, bitcoin will likely move in tandem with equities. "The current correlation regime may persist as long as global risk sentiment, central bank policy, and geopolitical flashpoints remain dominant market narratives," NYDIG's report said. For the maxis and long-term holders, the original vision hasn't changed. Bitcoin's limited supply, borderless access, and decentralized nature remain untouched. Just don't expect them to impact price action just yet. For now, the market sees bitcoin as just another stock ticker. Just balance your trade strategies accordingly. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
